Company news
Hemostemix Inc news in 2025
Hemostemix Inc's news releases, calls and decks from 2025, newest first.
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
December 31, 2025
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
December 23, 2025
Hemostemix: Granted Trademark 'KNOW YOUR HEALTH' in Japan.
December 18, 2025
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
December 18, 2025
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
December 18, 2025
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
December 11, 2025
Hemostemix Grants Stock Options
December 11, 2025
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
December 10, 2025
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
December 4, 2025
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
December 3, 2025
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
December 2, 2025
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
November 26, 2025
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
November 20, 2025
Hemostemix Closes CDN$280,594 Private Placement
November 18, 2025
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
November 18, 2025
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
November 13, 2025
Hemostemix Closes Private Placement of $461,230
November 4, 2025
Hemostemix's Boots on the Ground in Florida October Update
October 30, 2025
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
October 28, 2025
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
October 22, 2025
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
October 15, 2025
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
October 9, 2025
Hemostemix's Insider Lead Order of $330,000 Private Placement
October 7, 2025
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
September 23, 2025
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
September 18, 2025
Hemostemix to Present at Life Science Investor Forum
September 17, 2025
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
September 16, 2025
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
September 10, 2025
Hemostemix Announces Private Placement
September 9, 2025
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
September 9, 2025
Hemostemix's VesCell.Health Launched in Florida
September 4, 2025
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
September 3, 2025
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
August 28, 2025
Hemostemix's Boots on the Ground in Florida
August 26, 2025
Hemostemix's Social Media for Investors and Florida's No-Option Patients
August 20, 2025
Hemostemix Announces Its AI Strategy
August 19, 2025
Hemostemix's Expands its Marketing Team Focused on Sales in Florida
August 14, 2025
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
August 12, 2025
Hemostemix Increases Previously Closed Private Placement to $3,000,000
July 31, 2025
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
July 31, 2025
Hemostemix Closes $2,969,600 Private Placement
July 24, 2025
Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture
July 23, 2025
Hemostemix Closing $3,000,000 Private Placement
July 17, 2025
Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share
July 9, 2025
Hemostemix Closes $469,366 Private Placement
July 4, 2025
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial
July 3, 2025
Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
July 2, 2025
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
June 27, 2025
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
June 26, 2025
Hemostemix Closes Private Placement of $469,366
June 17, 2025
Decks in 2025
- Investor Presentation (2025)
Investor deck · 22 slides · Nov 3, 2025